Zimin Liu

机构：Qingdao University, Huazhong Agricultural University, Ansteel (China), Hunan Cancer Hospital, Affiliated Hospital of Qingdao University, Baosteel (China), Masteel (China), Xi'an Jiaotong University · ORCID：0000-0003-3104-4287

发表论文 94 篇 · 总被引 1841 次 · h-index 25

代表论文

• CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial (2025 · Nature Medicine · 被引 41)
• The Effect of Systemic Immune-Inflammatory Index (SII) and Prognostic Nutritional Index (PNI) in Early Gastric Cancer (2024 · Journal of Inflammation Research · 被引 38)
• Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 19)
• Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers (2024 · Cancer Immunology Immunotherapy · 被引 17)
• Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study (2024 · BMC Medicine · 被引 15)
• Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China (2024 · BMC Cancer · 被引 10)